Syneos Health and uMotif Partner to Deliver Patient-centric eClinical Platform
Integrated eCOA & ePRO Solution Taps Company’s Decentralized Capabilities and Technology ExpertiseMORRISVILLE, N.C., June 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health®...
Year: 2023
Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary SEDDS Technology Capsules for Canadian and International markets
Avicanna and Medipharm Labs Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary SEDDS Technology Capsules for Canadian...
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa First placebo-controlled randomized trial...
SPR Therapeutics Named a Top Workplace for Second Consecutive Year
- Company maintains focus on employee engagement and success while experiencing dynamic growth - CLEVELAND, June 25, 2023 (GLOBE NEWSWIRE)...
Novo Nordisk A/S: New data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials
After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec...
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396...
Enterin Presents Data Demonstrating Strong Benefit of ENT-03 on Body Weight, Adiposity and Blood Glucose Vs. Semaglutide in a Diet Induced Obesity Mouse Model
Data presented at the American Diabetes Association 83rd Scientific SessionsPHILADELPHIA, June 24, 2023 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held,...
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an...
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety and...
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on...
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
Daix (France), Long Island City (New York, United States), June 24, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a...
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an...
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions
– Once-weekly administration of CT-388 delivers clinically meaningful weight loss and metabolic control with a favorable tolerability profile over a...
XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company’s Upcoming Annual and Special Meeting of Shareholders
The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26,...
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase...
XOMA Added to the Russell 2000® and Russell 3000® Indexes
EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been...
Kane Biotech Announces Issuance of Restricted Share Units
WINNIPEG, Manitoba, June 23, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces...
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
Press Release No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer...
Biosenta Announces Entering Into of Agreement to Terminate Joint Venture
TORONTO, June 23, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (the “Company” or “Biosenta”) (CSE: ZRO) is pleased to announce that...
Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting
LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for...